Spyglass | Jotup

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on:

水曜日, 5月 1, 2024

FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points:

A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
"We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on:

水曜日, 5月 1, 2024

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points:

A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
"We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Retrieved on:

木曜日, 4月 11, 2024

Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications ( NCT06299761 ).

Key Points:

Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications ( NCT06299761 ).
ecDNA are a key driver of high copy number amplification in cancer, and Boundless has validated multiple drug targets that are essential for ecDNA function in cancer cells.
Boundless has identified an essential role for RNR in ecDNA assembly and repair and in the survival of certain oncogene amplified cancer cells.
“We are excited to enroll patients in this first-in-human Phase 1/2 study, focused initially on patients with KRASG12C and BRAFV600E mutated colorectal cancer with resistance gene amplifications.

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on:

火曜日, 4月 2, 2024

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points:

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
The SpyGlass platform was well tolerated and there were no adverse events related to the product.
These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
“SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.

SpyGlass Pharma Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform

Retrieved on:

火曜日, 12月 5, 2023

IOP, Cataract, Entrepreneurship, Food, FDA, MBA, Health, Intraocular pressure, Ocular hypertension, Ophthalmology, Device, Growth, Patient, Safety, Ahmad, KDB, Spyglass, Glaucoma, Management

Dr. Goodkin and Mr. Khan each bring a wealth of experience to support the growth and continued development of the SpyGlass intraocular drug delivery platform.

Key Points:

Dr. Goodkin and Mr. Khan each bring a wealth of experience to support the growth and continued development of the SpyGlass intraocular drug delivery platform.
Goodkin’s deep expertise in ophthalmic clinical development and regulatory proceedings make her uniquely qualified to lead our clinical program,” said Patrick Mooney, CEO of SpyGlass Pharma™.
Goodkin’s extensive leadership experience and personal conviction to improve patient care will enhance this company’s dedicated leadership team.
SpyGlass recently initiated a Phase I/II study to investigate the safety and efficacy of its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.

SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform

Retrieved on:

火曜日, 10月 31, 2023

FDA, Intraocular pressure, Ocular hypertension, Glaucoma, IOP, Entrepreneurship, Phase, Clinical trial, Bimatoprost, Safety, Patient, Cataract, Spyglass, Pharmaceutical industry, Medical device, IOL

ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.

Key Points:

ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.
The SpyGlass platform is designed to be implanted at the time of routine cataract surgery and deliver multiple years of bimatoprost, to lower intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
“The initiation of our Phase I/II study is an exciting and significant milestone for the company,” said Malik Y. Kahook, M.D., Co-Founder, Executive Chair and President of SpyGlass Pharma™.
“We are enthusiastic about conducting this vital research and working with the FDA to advance our platform through clinical development,” said Patrick Mooney, CEO of SpyGlass Pharma™.

Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on:

金曜日, 10月 13, 2023

BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.

Key Points:

BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.
BBI-825 has demonstrated RNR inhibition in a host of tumor cell lines and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being evaluated in Investigational New Drug (IND)-enabling studies.
BBI-825 was discovered using Boundless Bio’s proprietary Spyglass platform, a drug discovery engine to identify and preclinically validate targets that are essential for cancer cells’ reliance on ecDNA for growth, treatment resistance, and survival.
Details of today’s presentations are as follows:
Title: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRASG12C inhibitor in colorectal cancer (CRC)

Naval Maritime Autonomy Company Raises $55 Million in Series A Fundraise

Retrieved on:

火曜日, 10月 10, 2023

Multimedia, Navy, Lightspeed Venture Partners, Ecosystem, Growth, Saronic Gulf, Cutlass, Software, Research, Spyglass, Shipbuilding

AUSTIN, Texas, Oct. 10, 2023 /PRNewswire/ -- Saronic , a maritime autonomy company focused on surface vessels, announced today a $55 million Series A funding round led by Caffeinated Capital, with participation from 8VC, U.S.

Key Points:

AUSTIN, Texas, Oct. 10, 2023 /PRNewswire/ -- Saronic , a maritime autonomy company focused on surface vessels, announced today a $55 million Series A funding round led by Caffeinated Capital, with participation from 8VC, U.S.
"We have been astounded by the speed at which this exceptional team has already begun to bridge the technology gap in naval autonomy."
These systems enable real-time, collaborative, and autonomous mission-level decision-making, and are designed to navigate the challenges of maritime environments.
This investment reflects a strong belief in the team's capability to rapidly provide autonomous solutions tailored to the modern naval landscape.

Swirl Metasearch Version 2.0 Now Available with Connectors for Microsoft 365 Apps

Retrieved on:

木曜日, 6月 15, 2023

Transfer, SharePoint, Elastic, PostgreSQL, OpenSearch, Microsoft, Multimedia, Apache, Spyglass, OneDrive, BigQuery, Metasearch engine, ServiceNow, API, JetBrains, Online shopping, Swirl, Apache Solr, Atlassian

WALTHAM, Mass., June 15, 2023 /PRNewswire/ -- Swirl, the company behind the open-source Swirl Metasearch engine, today announced general availability of version 2.0, featuring enterprise-grade OAUTH2 support and pre-configured connectors to Microsoft 365 Outlook, OneDrive, Teams and SharePoint.

Key Points:

WALTHAM, Mass., June 15, 2023 /PRNewswire/ -- Swirl, the company behind the open-source Swirl Metasearch engine, today announced general availability of version 2.0, featuring enterprise-grade OAUTH2 support and pre-configured connectors to Microsoft 365 Outlook, OneDrive, Teams and SharePoint.
Swirl, the company behind the Swirl Metasearch engine, announced version 2.0 featuring Microsoft 365 integration.
"Swirl Metasearch solves cross-silo enterprise search problems without the massive time and effort required to copy and index data.
Swirl Metasearch is now available as a managed service.

Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023

Retrieved on:

月曜日, 4月 17, 2023

Boundless Bio , a clinical stage next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023.

Key Points:

Boundless Bio , a clinical stage next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023.
The poster “ Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition ” is available for in-person presentation on April 17, 2023 at 9:00 a.m. - 12:30 p.m.
"We are excited to unveil CHK1 as the ecDNA-essential target for our first novel ecDNA-directed therapy (ecDTx),” said Christian Hassig, Ph.D., Chief Scientific Officer of Boundless Bio.
We designed BBI-355, an orally available, highly potent, and selective inhibitor of CHK1 to target this unique genetic susceptibility in ecDNA-bearing cancer cells.